Environmental biotechnology is the branch of biotechnology that addresses environmental problems, such as the removal of pollution, renewable energy generation or biomass production, by exploiting ...

The bank appointed HSBC PLC as the global coordinator and Abu Dhabi Commercial Bank PJSC, Citigroup Global Markets Ltd, Crédit Agricole, Emirates NBD PJSC, Goldman Sachs, Islamic Corporation for the ...

Commissions do not affect our editors' opinions or evaluations. Biotech stocks are not for the faint of heart. These highly volatile equities can see stomach-churning price swings, driven by how ...

The biotech industry is primed for increased M ... Enrollment completion Phase 2b Study of Volixibat - Primary Sclerosing Cholangitis ("PSC") patients with Cholestatic Pruritus.

Amid the indefinite hunger strike of Jan Suraaj Party leader Prashant Kishor over the Bihar Public Service Commission (BPSC) Combined (Preliminary) Competitive Examination controversy, BPSC on ...

In 2024, Fierce Biotech reported 192 industry layoff rounds, which is 3% higher than in 2023, when 187 rounds were tallied. Rounds are reported as they are disclosed and are not combined per ...

UKPSC SI Admit Card 2025 OUT at psc.uk.gov.in: Uttarakhand Public Service Commission has released the admit card for Sub Inspector (Civil Police/Intelligence), Gulmanayak Male(PAC/IRB) under Home ...

Re­gen­eron, mak­er of the block­buster oph­thal­mol­o­gy med­i­cine Eylea, has ac­quired an oc­u­lar biotech, the large bio­phar­ma con­firmed to End­points News on Thurs­day.

No Oxular employees are joining Regeneron, though several will be “helping short-term with tech transfer and transition work in consulting roles,” a Regeneron spokesperson told Fierce Biotech ...

2024 was the year of the pri­vate megaround. Nine-fig­ure fi­nanc­ings dom­i­nat­ed biotech’s ven­ture fund­ing land­scape, with 96 such rounds tal­lied by End­points News. The bevy … ...

The biotechnology sector once again starts a new year on shaky footing. Acquisitions of publicly traded biotech companies have slowed. An anticipated upswing in initial public offerings hasn’t ...